§ Federal grant opportunity · HT942526DMDRPIDA

    DoW Duchenne Muscular Dystrophy, Idea Development Award

    Danielle Reckley Grantor is accepting applications for DoW Duchenne Muscular Dystrophy, Idea Development Award. The deadline is September 18, 2026 and the published award range is Award amount not published.

    Key facts

    Funder
    Danielle Reckley Grantor
    Application deadline
    September 18, 2026
    Award range
    Award amount not published
    Eligibility
    Eligibility criteria are published in the funding opportunity announcement.
    Geography
    United States
    Focus areas
    Research
    Opportunity number
    HT942526DMDRPIDA

    Program overview

    Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports impactful, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with Duchenne muscular dystrophy (DMD) in the near term. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale. The DMDRP strongly encourages research projects investigating therapies designed to demonstrate efficacy cross the life span, including infants, toddlers and nonambulatory individuals. Distinctive Features: The FY26 DMDRP IDA mechanism offers three eligibility career categories: • The Established Investigator category is for independent investigators at all academic levels, or equivalent • The New Investigator – Early-Stage category is for independent investigators early in their careers (i.e., within 10 years of their first faculty appointment or equivalent). Applicants in this category will be reviewed separately from Established Investigators. • The New Investigator – Transitioning category is for independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy who are seeking to transition to a career in DMD, thereby bringing their expertise to the field. Applicants in this category will be reviewed separately from Established Investigators. Preliminary data relevant to DMD that supports the feasibility of the research hypotheses and research approaches are required for all applications. Clinical trials or clinical trial aims are not allowed.

    How to apply

    1. Confirm your organization meets the eligibility criteria above.
    2. Read the full funding opportunity announcement from Danielle Reckley Grantor.
    3. Draft your narrative against the funder's stated priorities and review criteria.
    4. Submit before September 18, 2026, allowing time for registration and validation.

    View the official funding announcement

    Find every grant your organization qualifies for

    Mavenly scores this opportunity against your mission, geography, and funding history — then drafts the proposal with you and tracks the deadline through submission and reporting.